Welcome to our dedicated page for Glucotrack news (Ticker: GCTK), a resource for investors and traders seeking the latest updates and insights on Glucotrack stock.
GlucoTrack, Inc. (NASDAQ: GCTK) generates news primarily around its progress in implantable continuous blood glucose monitoring technology for people with diabetes and the financing activities that support this development. As a medical device and medical technology company, GlucoTrack regularly issues updates on clinical studies, advisory appointments, scientific presentations, and capital formation transactions.
Visitors to this GCTK news page can review press releases on clinical milestones, including GlucoTrack’s first-in-human study of its long-term implantable Continuous Blood Glucose Monitor (CBGM) and the initiation of a long-term, multicenter feasibility study outside the United States. The company also reports on its plans and interactions related to Investigational Device Exemption (IDE) submissions to the U.S. Food and Drug Administration, as described in its own forward-looking statements.
In addition to clinical updates, GlucoTrack publishes news about its clinical advisory team and patient engagement efforts, such as the appointment of specialists in cardiology, neuromodulation, and pain management, and the formation of a Patient Advisory Board. The company’s participation in diabetes-focused conferences and research initiatives, where it presents data on its blood-based, implantable CBGM system and epidural glucose monitoring work, is another frequent topic.
GlucoTrack’s news flow also covers financing and capital structure developments, including equity purchase agreements, private placements, and warrant repurchases described in its press releases and SEC filings. For investors and observers following GCTK, this page offers a consolidated view of GlucoTrack’s publicly disclosed corporate, clinical, and financial announcements related to its investigational CBGM platform and broader diabetes technology strategy.
Glucotrack (Nasdaq: GCTK), a medical technology company specializing in diabetes technologies, has announced its participation in the upcoming Q3 Virtual Investor Summit. Paul V. Goode, PhD, the company's President and CEO, will lead the presentation on Tuesday, September 16, 2025, at 1:30 PM ET.
The event will include a company presentation and one-on-one meetings with investors, providing an opportunity for stakeholders to learn more about Glucotrack's developments in diabetes technology.
Glucotrack (NASDAQ:GCTK), a medical technology company developing novel diabetes technologies, reported significant progress in Q2 2025. The company is preparing to launch a multicenter feasibility study of its fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025, followed by an FDA IDE submission in Q4 2025.
Key developments include strengthening the leadership team with Dr. David Hirsh as Medical Director-Cardiology and Dr. Victoria Carr-Brendel joining the Board. Clinical data presented at the ADA conference showed excellent accuracy with a MARD of 7.7% and 99% data capture rate. The company reported $9.6 million in cash as of June 30, 2025, sufficient to fund operations through 2025.
Financial results showed R&D expenses of $5.0 million and net loss of $11.6 million for H1 2025. The company strengthened its capital structure by repurchasing Series A Warrants to eliminate warrant liability and dilution concerns.
Glucotrack (NASDAQ:GCTK) has appointed Dr. David S. Hirsh as Medical Director of Cardiology to support the development of their Continuous Blood Glucose Monitor (CBGM). Dr. Hirsh, an experienced cardiac electrophysiologist from Harbin Clinical Cardiology Rome, brings extensive expertise in interventional cardiology procedures.
The appointment strengthens Glucotrack's clinical leadership as they advance their long-term implantable CBGM system, which is designed for up to three years of continuous monitoring. Unlike traditional monitors that measure glucose from interstitial fluid, Glucotrack's device measures directly from blood, aiming to provide real-time readings without lag time. The system features a unique intravascular placement approach and requires no wearable component.
Glucotrack (NASDAQ:GCTK) announced its participation in the 2025 Association of Diabetes Care and Education Specialists (ADCES) Annual Meeting from August 8-11, 2025 in Phoenix, AZ. The company will showcase its innovative Continuous Blood Glucose Monitor (CBGM) at Booth #1724 and present a scientific poster on endocrinologist perspectives regarding implantable monitoring technology.
Glucotrack's CBGM technology represents a significant advancement in diabetes management, offering a fully implantable solution that lasts up to three years. Unlike traditional CGMs that measure glucose in interstitial fluid through skin-worn devices, this system measures glucose directly from blood without requiring any external wearables. The company is preparing to begin its long-term early feasibility study following successful initial clinical validation.
Glucotrack (Nasdaq: GCTK) has announced the successful repurchase of over 90% of its outstanding Series A Warrants from warrant holders on June 30, 2025. The company repurchased approximately 49,700 Series A Warrants using existing cash, with about 4,300 warrants remaining outstanding. The warrants were originally issued as part of a $10M Public Offering in November 2024.
The repurchase is part of Glucotrack's capital formation strategy and demonstrates confidence in its development of a long-term implantable continuous blood glucose monitoring system for diabetes patients. The company's Series B Warrants were previously converted to common stock, as reported in Q1 2025.
Glucotrack (NASDAQ:GCTK) has announced positive final results from its first-in-human clinical study for its innovative Continuous Blood Glucose Monitor (CBGM) at the American Diabetes Association's 85th Scientific Sessions. The study demonstrated excellent accuracy with a MARD of 7.7% across 122 matched pairs and a 99% data capture rate, with no serious adverse events.
The implantable CBGM technology measures glucose directly from blood rather than interstitial fluid, eliminating typical lag time associated with traditional monitors. The study, conducted in Brazil from December 2024 to January 2025, included ten Type 1 or Type 2 diabetes patients. Analysis showed 92% of measurements in the green zone of the Diabetes Technology Society Error Grid, indicating high clinical accuracy.
The company plans to initiate a long-term early feasibility study in Q3 2025. The CBGM system is designed for a three-year sensor life with no on-body wearable component and minimal calibration requirements.
Glucotrack (NASDAQ: GCTK) has announced the election of Victoria E. Carr-Brendel, PhD to its Board of Directors, effective May 22, 2025. Dr. Carr-Brendel brings extensive experience in medical devices and implantable technologies, currently serving on Vicarious Surgical's board and previously leading Cochlear Implants at Sonova Group. She has held leadership positions at JenaValve Technology and Boston Scientific, with a career spanning roles at Dexcom and Baxter Healthcare.
Glucotrack is developing a long-term implantable Continuous Blood Glucose Monitoring (CBGM) system designed to function for up to three years without any wearable components. The system measures glucose directly from blood, aiming to provide real-time readings without the lag time associated with traditional interstitial fluid measurements. The device is currently in investigational status under U.S. law.
Glucotrack Inc. (NASDAQ: GCTK) has announced the formation of a Patient Advisory Board (PAB) to enhance the development of its long-term implantable Continuous Blood Glucose Monitor (CBGM). Following their successful first-in-human clinical study, the PAB will include individuals with direct diabetes experience to provide insights on product development and commercialization strategies.
The company's CBGM technology is designed as a long-term implantable system with no wearable component, offering up to three years of continuous monitoring. Unlike traditional monitors that measure glucose from interstitial fluid, Glucotrack's device measures directly from blood, potentially eliminating typical lag times in readings. The inaugural PAB meeting was held on May 3, 2025, with regular meetings planned to gather ongoing patient feedback.